Anavex生命科學 AVXL 深 滬
等待開盤 09-12 09:30:00 美东时间
9.58
+0.705
+7.94%
華盛通- 最 高9.655
- 今 開9.05
- 成交量 99.65万股
- 最 低 9.00
- 昨 收 8.875
- 總市值 8.18亿
- 52周最高 14.4405
- 市盈率 靜 --
- 換手率 1.17%
- 52周最低 5.03
- 委 比 -41.37%
- 總股本 8541.67万
- 歷史最高 31.50
- 量 比 0.78
- 振 幅 7.38%
- 歷史最低 0.60
- 每 手 1
- 風險率 1.30%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $46 price target.
09-10 19:31
Anavex Life Sciences Highlights New Clinical Precision Medicine Population 48-Week Data
New clinical Precision Medicine population 48-week data demonstrates unprecedented cognitive stabilization in early Alzheimer's diseaseCognitive outcomes observed in the oral blarcamesine 30 mg Precision Medicine cohort
09-09 19:36
Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
Anavex Life Sciences Corp., a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, announced that its CEO, Christopher U. Missling, PhD, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, in New York City. The presentation will be webcast live, with a replay available later. Anavex is advancing ANAVEX®2-73, a drug candidate targeting SI...
09-02 11:30
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
<p>Anavex Life Sciences Corp. announced a peer-reviewed publication in the journal *iScience* outlining how blarcamesine activates the sigma-1 receptor (S1R/SIGMAR1) to restore autophagy, a process disrupted in diseases like Alzheimer's. Studies confirm blarcamesine enhances autophagy in human cells and *C. elegans*, improving protein aggregation–related paralysis. The publication provides detailed biochemical evidence of the mechanism, highlight...
08-26 11:30
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows
Anavex published data showing blarcamesine prevented amyloid-related brain damage in mice, supporting SIGMAR1 as a target for Alzheimer's prevention.
08-20 19:31
Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer’s Disease
A study published in Neuroscience Letters demonstrates that blarcamesine prevents amyloid-beta-induced memory impairment and hippocampal oxidative damage in an Alzheimer's disease model. Pre-treatment with blarcamesine significantly reduced vulnerability to Aβ-induced oxidative stress and cognitive deficits. The drug works by activating SIGMAR1, which enhances autophagy, mitigates oxidative stress, and supports neurogenesis, potentially preventin...
08-20 11:30
Anavex Life Sciences Q3 EPS $(0.16) Misses $(0.14) Estimate
Anavex Life Sciences (NASDAQ:AVXL) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 11.89 percent. This is a 14.29 percent decrease over losses of $(0.14) per share
08-12 19:30
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Anavex Life Sciences Corp. reported its Q3 2025 financial results, highlighting progress in developing non-invasive treatments for Alzheimer's disease. The company presented positive data on blarcamesine, showing sustained benefits in early-stage Alzheimer's patients. Financially, the company has $101.2 million in cash, with an estimated 3+ years of cash runway. The net loss for the quarter was $13.2 million, or $0.16 per share, compared to $12.2...
08-12 11:30
